Who is sponsoring NCT00296322?

NCT00296322 is sponsored by Asan Medical Center.

What drugs are being tested in NCT00296322?

Interventions in NCT00296322: cisplatin, mitomycin-C, doxifluridine.

What condition does NCT00296322 study?

NCT00296322 studies Stomach Cancer.

Is NCT00296322 still recruiting?

NCT00296322 is currently completed. Last updated 6 January 2020.

Are results published for NCT00296322?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-01-06 · How we verify

NCT00296322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin

Completed Phase 3 Results posted Last updated 6 January 2020

What this trial tests

Phase 3 trial testing cisplatin, mitomycin-C, doxifluridine in Stomach Cancer in 528 participants. Completed in 1 March 2010.

Timeline

1 October 2001

Primary endpoint
1 December 2007

1 March 2010

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	528
Start date	1 October 2001
Primary completion	1 December 2007
Estimated completion	1 March 2010
Sites	1 location across South Korea

Drugs / interventions tested

cisplatin, mitomycin-C, doxifluridine — full drug profile →

Conditions studied

Stomach Cancer — all drugs for Stomach Cancer →

Sponsor

Asan Medical Center

Who can join

Adults 18 to 69, any sex, with Stomach Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Relapse-free Survival
Time frame: 3 years

Sponsor's own description

This study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine compared to mitomycin plus doxifluridine in resected advanced gastric cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stomach Cancer

Currently open trials in the same condition.

NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07310888 — Robotic Gastrectomy With 5th Arm · NA · recruiting
NCT07070466 — Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · Phase 2 · recruiting
NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
NCT06263088 — EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastroint · NA · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00296322 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 6 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00296322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing